Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis

Ross Penglase; Laila Girgis; Helen Englert; Xavier Brennan; Andrew Jabbour; Eugene Kotlyar; David Ma; John Moore

doi:10.1177/23971983221145639

Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis

J Scleroderma Relat Disord. 2023 Jun;8(2):87-100. doi: 10.1177/23971983221145639. Epub 2023 Feb 7.

Authors

Ross Penglase^{1

2

3}, Laila Girgis^{1

2

3}, Helen Englert⁴, Xavier Brennan⁵, Andrew Jabbour^{2

5}, Eugene Kotlyar^{2

5}, David Ma^{2

3

4}, John Moore^{2

3

4}

Affiliations

¹ Department of Rheumatology, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
² University of New South Wales, Sydney, NSW, Australia.
³ St. Vincent's Centre for Applied Medical Research, Darlinghurst, NSW, Australia.
⁴ Department of Haematology and BM Transplantation, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
⁵ Department of Cardiology and Heart and Lung Transplantation, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.

Abstract

Autologous haematopoietic stem cell transplantation is now well-established as an effective treatment for severe systemic sclerosis with clear demonstration of favourable end-organ and survival outcomes. Treatment-related cardiotoxicity remains the predominant safety concern and contraindicates autologous haematopoietic stem cell transplantation in patients with severe cardiopulmonary disease. In this review, we describe the cardiovascular outcomes of autologous haematopoietic stem cell transplantation recipients, discuss the potential mechanisms of cardiotoxicity and propose future mitigating strategies.

Keywords: Scleroderma; autologous haematopoietic stem cell transplantation; cardiac; safety; stem cell transplantation; systemic sclerosis; toxicity.

Publication types

Review